Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Nanjing Medical University200 enrolled

Overview

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Aneurysmal Subarachnoid Hemorrhage

Interventions

Antiplatelet DrugDRUG

aspirin and/or clopidogrel or ticagrelor

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment Exclusion Criteria: * 1\. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Locations (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

Montreal Cognitive Assessment (MoCA) Test

Time frame: 6-8 months

Central Contacts

Zhen Yu Jia, MD.

CONTACT

+86 13770918208 zhenyu_jia@sina.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.